Hannah Chang

Hannah Chang is a renowned figure in the healthcare venture capital industry, bringing a unique blend of expertise as a physician, scientist, and former management consultant. She has a strong educational background, having pursued a Doctor of Medicine (M.D.) at Harvard Medical School, a Doctor of Philosophy (Ph.D.) in Biophysics at Harvard University, and a Bachelor of Arts in Chemistry, graduating Summa cum laude from Princeton University. With roots in China and US training, Hannah Chang has made significant contributions across various organizations.

Currently serving as the Managing Director at Wu Capital (双湖资本), Hannah Chang has held key positions in several notable companies. She has served on the Board of Directors at IniPharm Pharmaceuticals, Korro Bio, Inc., Perfuse Therapeutics, PACT Pharma, Akouos, Gemini Therapeutics, and Semma Therapeutics. Additionally, she has previously worked as an Associate at 5AM Ventures, showcasing her diverse industry engagements.

Before her current role, Hannah Chang has accumulated rich experience in the healthcare sector. She has held the position of Project Leader at The Boston Consulting Group, focusing on the Health Care Practice. Furthermore, she has a background in medical practice, with roles as an Ophthalmology Resident at Massachusetts Eye and Ear Infirmary and an Internal Medicine Resident at Beth Israel Deaconess Medical Center.

Hannah Chang's deep understanding of both the medical and business aspects of the healthcare industry sets her apart. Her contributions to numerous organizations and ventures reflect her versatility and skillset, making her a respected professional in the field.